Actively Recruiting
Pilot Study of Pembrolizumab with Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma
Led by Dana-Farber Cancer Institute · Updated on 2026-02-20
15
Participants Needed
2
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating whether combining the investigational drug pembrolizumab with chemotherapy can help treat newly diagnosed primary central nervous system lymphoma PCNSL while managing side effects. This open-label pilot trial involves drugs including pembrolizumab, methotrexate, temozolomide, and rituximab. Although pembrolizumab is not FDA-approved for PCNSL, it is approved for other uses, and rituximab is approved for PCNSL. The study involves about 15 participants and is supported by Merck 26 Co.
CONDITIONS
Brief Title
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Research Team
L
Lakshmi Nayak, MD
D
DFCI Clinical Trials Hotline
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
